Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma.

Cuccarini V, Aquino D, Gioppo A, Anghileri E, Pellegatta S, Schettino C, Mazzi F, Finocchiaro G, Bruzzone MG, Eoli M.

J Clin Med. 2019 Nov 17;8(11). pii: E2007. doi: 10.3390/jcm8112007.

2.

Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.

Liu ZC, Yan LF, Hu YC, Sun YZ, Tian Q, Nan HY, Yu Y, Sun Q, Wang W, Cui GB.

BMC Med Imaging. 2017 Feb 1;17(1):10. doi: 10.1186/s12880-017-0183-y.

3.

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.

Kebir S, Fimmers R, Galldiks N, Schäfer N, Mack F, Schaub C, Stuplich M, Niessen M, Tzaridis T, Simon M, Stoffels G, Langen KJ, Scheffler B, Glas M, Herrlinger U.

Clin Cancer Res. 2016 May 1;22(9):2190-6. doi: 10.1158/1078-0432.CCR-15-1334. Epub 2015 Dec 16.

4.

Interval Change in Diffusion and Perfusion MRI Parameters for the Assessment of Pseudoprogression in Cerebral Metastases Treated With Stereotactic Radiation.

Knitter JR, Erly WK, Stea BD, Lemole GM, Germano IM, Doshi AH, Nael K.

AJR Am J Roentgenol. 2018 Jul;211(1):168-175. doi: 10.2214/AJR.17.18890. Epub 2018 Apr 30.

PMID:
29708785
5.

Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.

Nasseri M, Gahramanov S, Netto JP, Fu R, Muldoon LL, Varallyay C, Hamilton BE, Neuwelt EA.

Neuro Oncol. 2014 Aug;16(8):1146-54. doi: 10.1093/neuonc/not328. Epub 2014 Feb 11.

6.

Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.

Rowe LS, Butman JA, Mackey M, Shih JH, Cooley-Zgela T, Ning H, Gilbert MR, Smart DK, Camphausen K, Krauze AV.

J Neurooncol. 2018 Aug;139(1):145-152. doi: 10.1007/s11060-018-2855-z. Epub 2018 May 16.

PMID:
29767308
8.

True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis.

Song YS, Choi SH, Park CK, Yi KS, Lee WJ, Yun TJ, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Jahng GH, Chang KH.

Korean J Radiol. 2013 Jul-Aug;14(4):662-72. doi: 10.3348/kjr.2013.14.4.662. Epub 2013 Jul 17.

9.

Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.

Kong Z, Yan C, Zhu R, Wang J, Wang Y, Wang Y, Wang R, Feng F, Ma W.

Neuroimage Clin. 2018 Jul 5;20:51-60. doi: 10.1016/j.nicl.2018.07.001. eCollection 2018. Review.

10.

Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps.

Reimer C, Deike K, Graf M, Reimer P, Wiestler B, Floca RO, Kickingereder P, Schlemmer HP, Wick W, Bendszus M, Radbruch A.

PLoS One. 2017 Apr 6;12(4):e0174620. doi: 10.1371/journal.pone.0174620. eCollection 2017.

11.

Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.

Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER.

Oncologist. 2014 Jan;19(1):75-81. doi: 10.1634/theoncologist.2013-0101. Epub 2013 Dec 5.

12.

Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.

Qin L, Li X, Stroiney A, Qu J, Helgager J, Reardon DA, Young GS.

Neuroradiology. 2017 Feb;59(2):135-145. doi: 10.1007/s00234-016-1769-8. Epub 2017 Jan 9.

13.

Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.

Wang S, Martinez-Lage M, Sakai Y, Chawla S, Kim SG, Alonso-Basanta M, Lustig RA, Brem S, Mohan S, Wolf RL, Desai A, Poptani H.

AJNR Am J Neuroradiol. 2016 Jan;37(1):28-36. doi: 10.3174/ajnr.A4474. Epub 2015 Oct 8.

14.

DC-AL GAN: Pseudoprogression and true tumor progression of glioblastoma multiform image classification based on DCGAN and AlexNet.

Li M, Tang H, Chan MD, Zhou X, Qian X.

Med Phys. 2019 Dec 29. doi: 10.1002/mp.14003. [Epub ahead of print]

PMID:
31885094
15.

Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.

Choi YJ, Kim HS, Jahng GH, Kim SJ, Suh DC.

Acta Radiol. 2013 May;54(4):448-54. doi: 10.1177/0284185112474916. Epub 2013 Apr 30.

PMID:
23592805
16.

Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.

Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H.

Am J Clin Oncol. 2017 Jun;40(3):228-234. doi: 10.1097/COC.0000000000000156.

PMID:
25436828
17.

Visual assessment of magnetic resonance imaging perfusion lesions in a large patient group.

Siemonsen S, Fitting T, Thomalla G, Krützelmann A, Fiehler J.

Clin Neuroradiol. 2012 Dec;22(4):305-13. doi: 10.1007/s00062-012-0143-4. Epub 2012 Apr 8.

PMID:
22484907
18.

MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.

Aquino D, Gioppo A, Finocchiaro G, Bruzzone MG, Cuccarini V.

J Immunol Res. 2017;2017:5813951. doi: 10.1155/2017/5813951. Epub 2017 Apr 20. Review.

19.

Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.

Chu HH, Choi SH, Ryoo I, Kim SC, Yeom JA, Shin H, Jung SC, Lee AL, Yoon TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, Kim IH.

Radiology. 2013 Dec;269(3):831-40. doi: 10.1148/radiol.13122024. Epub 2013 Oct 28.

PMID:
23771912
20.

Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.

Kim JY, Park JE, Jo Y, Shim WH, Nam SJ, Kim JH, Yoo RE, Choi SH, Kim HS.

Neuro Oncol. 2019 Feb 19;21(3):404-414. doi: 10.1093/neuonc/noy133.

PMID:
30107606

Supplemental Content

Support Center